StoneX Group’s Adial Pharmaceuticals ADIL Stock Holding History

StoneX Group’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-778	Closed	-$4.28K	–	921
2025 Q4	$4.28K	Buy	+778	New	+$6.3K	﹤0.01%	1040
2022 Q4	–	Sell	-22	Closed	-$4.83K	–	588
2022 Q3	$4.83K	Sell	22 -2	-8%	-$902	﹤0.01%	314
2022 Q2	$20.1K	Buy	+24	New	+$21.7K	﹤0.01%	435

Other funds holding ADIL

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

MCM

Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

StoneX Group's ADIL Position: Q1 2026 in Review

StoneX Group sold out of Adial Pharmaceuticals (ADIL) in Q1 2026, closing a stake of 778 shares — an estimated $4.28K sold.

StoneX Group first reported a position in ADIL in Q2 2022 and held it in 3 quarters. The position peaked at $20.1K in Q2 2022. 14 funds tracked by Wall St. Rank hold ADIL as of Q1 2026.

StoneX Group reported no remaining Adial Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
StoneX Group sold 778 Adial Pharmaceuticals shares in Q1 2026, an estimated $4.28K.
StoneX Group first reported a position in Adial Pharmaceuticals in Q2 2022 and held it in 3 quarters.
StoneX Group's Adial Pharmaceuticals position peaked at $20.1K in Q2 2022.
14 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.